Health Care·Biotechnology·$20.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.19 | N/A | +110.73% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.19 | N/A | +110.73% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a cautiously optimistic outlook, focusing on innovation and future opportunities despite market challenges.
Management highlighted the importance of continued innovation in their pipeline.
They acknowledged the challenges in the current market but expressed confidence in future growth.
Moderna's earnings report showed a strong EPS performance, exceeding expectations significantly. The stock reacted positively, rising by 3.22%, likely driven by the surprise in earnings. However, the lack of revenue data and guidance may leave investors cautious about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
STRYKER CORP
May 1, 2023